BIOTECH
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
January 9, 2023
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines...